https://stock.noler.com/us/stock/4d-pharma-plc https://stock.noler.com/us/stock/4d-pharma-plc/13f-holdings-corporate-securities https://stock.noler.com/us/stock/4d-pharma-plc/accounts-payable https://stock.noler.com/us/stock/4d-pharma-plc/accrued-income-taxes-current https://stock.noler.com/us/stock/4d-pharma-plc/accrued-liabilities-and-other-liabilities https://stock.noler.com/us/stock/4d-pharma-plc/accrued-payroll-taxes-current https://stock.noler.com/us/stock/4d-pharma-plc/accrued-professional-fees-current https://stock.noler.com/us/stock/4d-pharma-plc/accumulated-depreciation https://stock.noler.com/us/stock/4d-pharma-plc/acquisitions https://stock.noler.com/us/stock/4d-pharma-plc/additional-paid-in-capital https://stock.noler.com/us/stock/4d-pharma-plc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/4d-pharma-plc/amended-reports https://stock.noler.com/us/stock/4d-pharma-plc/amortization https://stock.noler.com/us/stock/4d-pharma-plc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/4d-pharma-plc/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/4d-pharma-plc/aoci https://stock.noler.com/us/stock/4d-pharma-plc/asset-retirement-obligation-accretion-expense https://stock.noler.com/us/stock/4d-pharma-plc/asset-retirement-obligations-noncurrent https://stock.noler.com/us/stock/4d-pharma-plc/auditor https://stock.noler.com/us/stock/4d-pharma-plc/authorized-dilution https://stock.noler.com/us/stock/4d-pharma-plc/beta https://stock.noler.com/us/stock/4d-pharma-plc/borrowing-debt https://stock.noler.com/us/stock/4d-pharma-plc/buybacks-repurchase-programs https://stock.noler.com/us/stock/4d-pharma-plc/capital-expenditures https://stock.noler.com/us/stock/4d-pharma-plc/cash-and-equivalents https://stock.noler.com/us/stock/4d-pharma-plc/cash-and-restricted-cash-including-disposal-group-and-discontinued-operations https://stock.noler.com/us/stock/4d-pharma-plc/cash-and-securities https://stock.noler.com/us/stock/4d-pharma-plc/cash-flow-breakdown https://stock.noler.com/us/stock/4d-pharma-plc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/4d-pharma-plc/clinical-trials https://stock.noler.com/us/stock/4d-pharma-plc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/4d-pharma-plc/common-stock-value https://stock.noler.com/us/stock/4d-pharma-plc/comprehensive-income https://stock.noler.com/us/stock/4d-pharma-plc/concentration-risk-percentage https://stock.noler.com/us/stock/4d-pharma-plc/congressional-trades https://stock.noler.com/us/stock/4d-pharma-plc/convertible-securities-outstanding https://stock.noler.com/us/stock/4d-pharma-plc/convertible-securities-retired https://stock.noler.com/us/stock/4d-pharma-plc/cover-page-shares-outstanding https://stock.noler.com/us/stock/4d-pharma-plc/current-assets https://stock.noler.com/us/stock/4d-pharma-plc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/4d-pharma-plc/current-liabilities https://stock.noler.com/us/stock/4d-pharma-plc/customer-breakdown https://stock.noler.com/us/stock/4d-pharma-plc/debt-and-obligation-disclosures https://stock.noler.com/us/stock/4d-pharma-plc/deferred-costs https://stock.noler.com/us/stock/4d-pharma-plc/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/4d-pharma-plc/deferred-income-tax-liabilities-net https://stock.noler.com/us/stock/4d-pharma-plc/deferred-revenue https://stock.noler.com/us/stock/4d-pharma-plc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/4d-pharma-plc/deferred-revenue-recognized https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-assets-in-process-research-and-development https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-assets-operating-loss-carryforwards-domestic https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-assets-other https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-warranty-reserves https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/4d-pharma-plc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/4d-pharma-plc/depreciation https://stock.noler.com/us/stock/4d-pharma-plc/depreciation-and-amortization https://stock.noler.com/us/stock/4d-pharma-plc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/4d-pharma-plc/derivative-gain-loss-on-derivative-net https://stock.noler.com/us/stock/4d-pharma-plc/derivative-liabilities https://stock.noler.com/us/stock/4d-pharma-plc/derivative-liabilities-noncurrent https://stock.noler.com/us/stock/4d-pharma-plc/dividend-safety https://stock.noler.com/us/stock/4d-pharma-plc/earnings-and-revenue-growth https://stock.noler.com/us/stock/4d-pharma-plc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/4d-pharma-plc/ebitda https://stock.noler.com/us/stock/4d-pharma-plc/effective-tax-rate https://stock.noler.com/us/stock/4d-pharma-plc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/4d-pharma-plc/executive-pay-measures https://stock.noler.com/us/stock/4d-pharma-plc/executive-pay-other https://stock.noler.com/us/stock/4d-pharma-plc/executive-pay-pvp https://stock.noler.com/us/stock/4d-pharma-plc/executive-pay-trading-arrangements https://stock.noler.com/us/stock/4d-pharma-plc/executive-salary-before-2006 https://stock.noler.com/us/stock/4d-pharma-plc/executive-salary-board https://stock.noler.com/us/stock/4d-pharma-plc/executive-salary-equity-awards https://stock.noler.com/us/stock/4d-pharma-plc/executive-salary-officers https://stock.noler.com/us/stock/4d-pharma-plc/executive-salary-other-compensation https://stock.noler.com/us/stock/4d-pharma-plc/executive-salary-other-mentions https://stock.noler.com/us/stock/4d-pharma-plc/executive-salary-pay-ratio https://stock.noler.com/us/stock/4d-pharma-plc/executive-salary-relatives https://stock.noler.com/us/stock/4d-pharma-plc/fails-to-deliver https://stock.noler.com/us/stock/4d-pharma-plc/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/4d-pharma-plc/fair-value-measurement-with-unobservable-inputs-reconciliations-recurring-basis-liability-value https://stock.noler.com/us/stock/4d-pharma-plc/financing-cash-flow https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-amortization-expense-remainder-of-fiscal-year https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/4d-pharma-plc/finite-lived-intangible-assets-translation-and-purchase-accounting-adjustments https://stock.noler.com/us/stock/4d-pharma-plc/finitelived-intangible-assets-acquired https://stock.noler.com/us/stock/4d-pharma-plc/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/4d-pharma-plc/foreign-currency-transaction-gain-loss-realized https://stock.noler.com/us/stock/4d-pharma-plc/free-cash-flow https://stock.noler.com/us/stock/4d-pharma-plc/gain-loss-on-disposition-of-intangible-assets https://stock.noler.com/us/stock/4d-pharma-plc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/4d-pharma-plc/goodwill https://stock.noler.com/us/stock/4d-pharma-plc/goodwill-translation-and-purchase-accounting-adjustments https://stock.noler.com/us/stock/4d-pharma-plc/gross-margin https://stock.noler.com/us/stock/4d-pharma-plc/holders-breakdown https://stock.noler.com/us/stock/4d-pharma-plc/income-tax https://stock.noler.com/us/stock/4d-pharma-plc/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/4d-pharma-plc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/4d-pharma-plc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/4d-pharma-plc/increase-decrease-in-operating-capital https://stock.noler.com/us/stock/4d-pharma-plc/increase-decrease-in-operating-lease-liability https://stock.noler.com/us/stock/4d-pharma-plc/increase-decrease-in-other-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/4d-pharma-plc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/4d-pharma-plc/insider-holders https://stock.noler.com/us/stock/4d-pharma-plc/insider-transactions-corporate-securities https://stock.noler.com/us/stock/4d-pharma-plc/insider-transactions-other https://stock.noler.com/us/stock/4d-pharma-plc/insider-transactions-preferred https://stock.noler.com/us/stock/4d-pharma-plc/insider-transactions-stock-options https://stock.noler.com/us/stock/4d-pharma-plc/insider-transactions-stock-units https://stock.noler.com/us/stock/4d-pharma-plc/insider-transactions-swaps-forwards-futures https://stock.noler.com/us/stock/4d-pharma-plc/insider-transactions-warrants https://stock.noler.com/us/stock/4d-pharma-plc/institutional-holders https://stock.noler.com/us/stock/4d-pharma-plc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/4d-pharma-plc/interest-expense https://stock.noler.com/us/stock/4d-pharma-plc/interest-income-other https://stock.noler.com/us/stock/4d-pharma-plc/interest-paid-net https://stock.noler.com/us/stock/4d-pharma-plc/investing-cash-flow https://stock.noler.com/us/stock/4d-pharma-plc/iran-activity-notices https://stock.noler.com/us/stock/4d-pharma-plc/late-filing-notices https://stock.noler.com/us/stock/4d-pharma-plc/lawsuits-defendant https://stock.noler.com/us/stock/4d-pharma-plc/lawsuits-plaintiff https://stock.noler.com/us/stock/4d-pharma-plc/lease-cost https://stock.noler.com/us/stock/4d-pharma-plc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/4d-pharma-plc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/4d-pharma-plc/level-3-liability-gain-loss-included-in-earnings https://stock.noler.com/us/stock/4d-pharma-plc/level-3-liability-gain-loss-included-in-other-comprehensive-income https://stock.noler.com/us/stock/4d-pharma-plc/major-holders https://stock.noler.com/us/stock/4d-pharma-plc/material-contracts https://stock.noler.com/us/stock/4d-pharma-plc/mentioned-by-other https://stock.noler.com/us/stock/4d-pharma-plc/mutual-fund-holders https://stock.noler.com/us/stock/4d-pharma-plc/net-change-in-cash https://stock.noler.com/us/stock/4d-pharma-plc/net-income https://stock.noler.com/us/stock/4d-pharma-plc/news https://stock.noler.com/us/stock/4d-pharma-plc/obligation-breakdown https://stock.noler.com/us/stock/4d-pharma-plc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/4d-pharma-plc/oci-net-of-tax https://stock.noler.com/us/stock/4d-pharma-plc/operating-cash-flow https://stock.noler.com/us/stock/4d-pharma-plc/operating-expenses https://stock.noler.com/us/stock/4d-pharma-plc/operating-income https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-assets https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-cost https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-liability https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-liability-current https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-payments https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-payments-due https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/4d-pharma-plc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/4d-pharma-plc/operating-margin https://stock.noler.com/us/stock/4d-pharma-plc/other https://stock.noler.com/us/stock/4d-pharma-plc/other-accrued-liabilities-current https://stock.noler.com/us/stock/4d-pharma-plc/other-assets https://stock.noler.com/us/stock/4d-pharma-plc/other-current-assets https://stock.noler.com/us/stock/4d-pharma-plc/other-income https://stock.noler.com/us/stock/4d-pharma-plc/other-noncurrent-liabilities https://stock.noler.com/us/stock/4d-pharma-plc/other-nonoperating-income-expense https://stock.noler.com/us/stock/4d-pharma-plc/other-prepaid-expense-current https://stock.noler.com/us/stock/4d-pharma-plc/outstanding-bonds https://stock.noler.com/us/stock/4d-pharma-plc/outstanding-bonds-foreign https://stock.noler.com/us/stock/4d-pharma-plc/outstanding-bonds-matured https://stock.noler.com/us/stock/4d-pharma-plc/outstanding-bonds-matured-foreign https://stock.noler.com/us/stock/4d-pharma-plc/outstanding-bonds-matured-unclassified https://stock.noler.com/us/stock/4d-pharma-plc/outstanding-bonds-unclassified https://stock.noler.com/us/stock/4d-pharma-plc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/4d-pharma-plc/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/4d-pharma-plc/patents https://stock.noler.com/us/stock/4d-pharma-plc/patents-active https://stock.noler.com/us/stock/4d-pharma-plc/patents-expired https://stock.noler.com/us/stock/4d-pharma-plc/patents-pending https://stock.noler.com/us/stock/4d-pharma-plc/patents-rejected https://stock.noler.com/us/stock/4d-pharma-plc/payables-and-obligations https://stock.noler.com/us/stock/4d-pharma-plc/payments-for-proceeds-from-investments https://stock.noler.com/us/stock/4d-pharma-plc/payments-for-software https://stock.noler.com/us/stock/4d-pharma-plc/payments-of-debt-issuance-costs https://stock.noler.com/us/stock/4d-pharma-plc/payments-of-merger-related-costs-financing-activities https://stock.noler.com/us/stock/4d-pharma-plc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/4d-pharma-plc/pb-ratio https://stock.noler.com/us/stock/4d-pharma-plc/pe-ratio https://stock.noler.com/us/stock/4d-pharma-plc/preferred-shares https://stock.noler.com/us/stock/4d-pharma-plc/preferred-shares-facts https://stock.noler.com/us/stock/4d-pharma-plc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/4d-pharma-plc/prepaid-expense-current https://stock.noler.com/us/stock/4d-pharma-plc/prepaid-insurance https://stock.noler.com/us/stock/4d-pharma-plc/prepaid-taxes https://stock.noler.com/us/stock/4d-pharma-plc/pretax-income https://stock.noler.com/us/stock/4d-pharma-plc/proceeds-from-issuance-of-warrants https://stock.noler.com/us/stock/4d-pharma-plc/proceeds-from-repayments-of-debt https://stock.noler.com/us/stock/4d-pharma-plc/proceeds-from-sale-of-productive-assets https://stock.noler.com/us/stock/4d-pharma-plc/proceeds-from-stock-issued https://stock.noler.com/us/stock/4d-pharma-plc/proceeds-from-warrant-exercises https://stock.noler.com/us/stock/4d-pharma-plc/property-plant-and-equipment-disposals https://stock.noler.com/us/stock/4d-pharma-plc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/4d-pharma-plc/property-plant-equipment https://stock.noler.com/us/stock/4d-pharma-plc/ps-ratio https://stock.noler.com/us/stock/4d-pharma-plc/quick-ratio https://stock.noler.com/us/stock/4d-pharma-plc/recapitalization-costs https://stock.noler.com/us/stock/4d-pharma-plc/reddit https://stock.noler.com/us/stock/4d-pharma-plc/repayments-of-debt-and-capital-lease-obligations https://stock.noler.com/us/stock/4d-pharma-plc/research-and-development https://stock.noler.com/us/stock/4d-pharma-plc/retained-earnings https://stock.noler.com/us/stock/4d-pharma-plc/revenue https://stock.noler.com/us/stock/4d-pharma-plc/sec-comment-letters https://stock.noler.com/us/stock/4d-pharma-plc/sec-enforcement-actions https://stock.noler.com/us/stock/4d-pharma-plc/sec-filings https://stock.noler.com/us/stock/4d-pharma-plc/sga-expense https://stock.noler.com/us/stock/4d-pharma-plc/share-buybacks https://stock.noler.com/us/stock/4d-pharma-plc/shareholder-equity https://stock.noler.com/us/stock/4d-pharma-plc/shareholders-equity https://stock.noler.com/us/stock/4d-pharma-plc/shares-authorized https://stock.noler.com/us/stock/4d-pharma-plc/shares-issued https://stock.noler.com/us/stock/4d-pharma-plc/shares-issued-price-per-share https://stock.noler.com/us/stock/4d-pharma-plc/shares-issued-shares-new-issues https://stock.noler.com/us/stock/4d-pharma-plc/shares-outstanding-analysis https://stock.noler.com/us/stock/4d-pharma-plc/short-interest https://stock.noler.com/us/stock/4d-pharma-plc/short-sale-volume https://stock.noler.com/us/stock/4d-pharma-plc/short-term-lease-cost https://stock.noler.com/us/stock/4d-pharma-plc/short-term-lease-payments https://stock.noler.com/us/stock/4d-pharma-plc/spending-and-interest-coverage https://stock.noler.com/us/stock/4d-pharma-plc/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/4d-pharma-plc/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/4d-pharma-plc/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/4d-pharma-plc/stock-award-non-option-equity-instruments-exercised https://stock.noler.com/us/stock/4d-pharma-plc/stock-award-non-option-equity-instruments-granted https://stock.noler.com/us/stock/4d-pharma-plc/stock-award-non-option-equity-instruments-outstanding-number https://stock.noler.com/us/stock/4d-pharma-plc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/4d-pharma-plc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/4d-pharma-plc/stock-based-compensation https://stock.noler.com/us/stock/4d-pharma-plc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/4d-pharma-plc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/4d-pharma-plc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-exercisable-number https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-nonvested-grant-date-fair-value https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-nonvested-number-of-shares https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-nonvested-options-forfeited-grant-date-fair-value https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-nonvested-options-forfeited-number-of-shares https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-outstanding-number https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-vested-and-expected-to-vest-exercisable-average-exercise-price https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-vested-grant-date-fair-value https://stock.noler.com/us/stock/4d-pharma-plc/stock-options-vested-number-of-shares https://stock.noler.com/us/stock/4d-pharma-plc/subsidiaries https://stock.noler.com/us/stock/4d-pharma-plc/supplier-breakdown https://stock.noler.com/us/stock/4d-pharma-plc/supplies https://stock.noler.com/us/stock/4d-pharma-plc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/4d-pharma-plc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/4d-pharma-plc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/4d-pharma-plc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/4d-pharma-plc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/4d-pharma-plc/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/4d-pharma-plc/tax-rate-reconciliation-tax-exempt-income https://stock.noler.com/us/stock/4d-pharma-plc/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/4d-pharma-plc/tax-reconciliation-nondeductible-expense-research-and-development https://stock.noler.com/us/stock/4d-pharma-plc/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/4d-pharma-plc/tax-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/4d-pharma-plc/tax-reconciliation-tax-exempt-income https://stock.noler.com/us/stock/4d-pharma-plc/total-assets https://stock.noler.com/us/stock/4d-pharma-plc/total-contract-liability https://stock.noler.com/us/stock/4d-pharma-plc/total-liabilities https://stock.noler.com/us/stock/4d-pharma-plc/total-liabilities-and-equity https://stock.noler.com/us/stock/4d-pharma-plc/total-long-term-debt https://stock.noler.com/us/stock/4d-pharma-plc/unrecognized-tax-benefits https://stock.noler.com/us/stock/4d-pharma-plc/utb-income-tax-penalties-and-interest-accrued https://stock.noler.com/us/stock/4d-pharma-plc/value-added-tax-receivable-noncurrent https://stock.noler.com/us/stock/4d-pharma-plc/voting-outcome https://stock.noler.com/us/stock/4d-pharma-plc/warrants-and-rights-outstanding https://stock.noler.com/us/stock/4d-pharma-plc/weighted-average-number-of-share-outstanding-basic-and-diluted https://stock.noler.com/us/stock/4d-pharma-plc/youtube